ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2764

Medication Necessity and Concerns Beliefs Are Distinct, Interactive Predictors of Treatment Adherence in Rheumatoid Arthritis

George Karpouzas1, Elizabeth Hernandez 2, Lorena Ruiz 3, Vibeke Strand 4 and Sarah Ormseth 1, 1Harbor-UCLA Medical Center and Los Angeles Biomedical Institute, Torrance, CA, 2Harbor-UCLA and Los Angeles Biomedical Institute, Torrance, CA, 3Harbor-UCLA andLos Angeles Biomedical Research Institute, Torrance, 4Division of Immunology/Rheumatology, Stanford University, Stanford, CA

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: beliefs and adherence, medication, Rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 12, 2019

Title: 5T091: Patient Outcomes, Preferences, & Attitudes II: Patient Preferences, Beliefs, & Experiences (2762–2767)

Session Type: ACR Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose: Medication adherence is instrumental for the successful management of rheumatoid arthritis (RA) to a goal of remission. Awareness of medication necessity and concerns regarding its use influence adherence and respectively foster or undermine the achievement of treatment goals. We here explored the unique and interactive roles of patient beliefs about the necessity of RA medications and concerns about them in predicting adherence to prescribed treatments.

Methods: We evaluated 316 patients with established RA from a single center. Beliefs about the necessity of RA medications and concerns regarding their use were evaluated with the Beliefs about Medicines Questionnaire-Specific (BMQ) Necessity and Concerns scales (range 5-25). Self-reported rheumatoid arthritis treatment adherence was assessed using the Simplified Medication Adherence Questionnaire (SMAQ, range 0-6). Multivariable linear regression evaluated the effects of necessity, concerns and their interactions with adherence. A latent profile analysis (LPA) subsequently classified patients in groups according to patterns of necessity and concerns; adherence scores were then compared across latent groups using analysis of covariance (ANCOVA). 

Results: Full adherence (SMAQ score 6/6) was reported by 101 (32%) patients. Necessity and concerns had independent and opposing contributions to adherence (β=0.21 and β=-0.28 respectively, both p< 0.001, figure 1a) even after adjustments for age, gender and disease duration. An interaction between necessity and concerns with adherence was also observed (p=0.009); post-hoc simple-slope tests indicated that necessity predicted adherence in the context of increasing concerns. The Johnson-Neyman technique revealed that while concerns were significantly associated with adherence across the entire range of necessity scores,necessity was significantly related to adherence only at high BMQ Concerns scores (³13 ).LPA revealed four latent patient groups (figure 1b): Low necessity/ Low concerns (indifferent, n=33), Low necessity/ High concerns (skeptical, n=70), High necessity/ High concerns (ambivalent, n=92) and High necessity/ Low concerns (accepting, n=121). Adherence varied across groups even after adjusting for between-group differences (p=0.002, Figure 1c); adherence was highest in the accepting group and lowest in the skeptical group.

Conclusion: The relationship between necessity and concern beliefs regarding RA medications significantly influences adherence behavior and may further direct physicians to effectively tailor their education efforts in diverse patient groups. A message aimed at reducing concerns might be more effective in the ambivalent group, whereas emphasizing medication necessity may be more fruitful in the skeptical group.


Disclosure: G. Karpouzas, Bristol Meyer Squibb, 8, bristol Meyer Squibb, 8, Bristol-Meyer-Squibb, 8, Pfizer, 2, 9, pfizer, 2, Sanofi, 5, 8; E. Hernandez, None; L. Ruiz, None; V. Strand, Abbvie, 5, AbbVie, 5, Amgen, 5, Amgen, Abbvie, Bayer, BMS, Boehringer Ingelheim, Celltrion, Janssen, Lilly, Merck, Novartis, Pfizer, Regeneron, Samsung, Sandoz, Sanofi, UCB, 5, AstraZeneca, 5, AURA, 8, Bayer, 5, BMS, 5, Boehringer Ingelheim, 5, Celgene, 5, Celltrion, 5, Cleveland Clinic, 8, CORRONA, 5, Crescendo, 5, Crescendo Bioscience, 5, Eli Lilly, 5, EMD Serono, 5, Genentech, 5, GlaxoSmithKline, 5, GSK, 5, Horizon, 5, Inmedix, 5, Janssen, 5, Kezar, 5, Lilly, 5, Merck, 5, NACCME, 8, Novartis, 5, Pfizer, 5, Purdue, 8, RA Forum, 8, RAN, 8, Regeneron, 5, Roche, 5, Samsung, 5, Sandoz, 5, Sanofi, 5, Servier, 5, Setpoint, 5, SLRA, 8, UCB, 5, Up to Date, 7, Washington University, 8, WIR, 8, WRA, 8; S. Ormseth, None.

To cite this abstract in AMA style:

Karpouzas G, Hernandez E, Ruiz L, Strand V, Ormseth S. Medication Necessity and Concerns Beliefs Are Distinct, Interactive Predictors of Treatment Adherence in Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/medication-necessity-and-concerns-beliefs-are-distinct-interactive-predictors-of-treatment-adherence-in-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/medication-necessity-and-concerns-beliefs-are-distinct-interactive-predictors-of-treatment-adherence-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology